Morphosys: Prelim 2022 Monjuvi U.S. Net Product Sales, 2023 Financial Guidance

 

• Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million (€ 84.9 million)
• Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million
• Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 220 million which represents a reduction of € 360 million

https://www.marketscreener.com/quote/stock/MORPHOSYS-AG-436425/news/MorphoSys-Reports-Preliminary-2022-Monjuvi-U-S-Net-Product-Sales-Provides-2023-Financial-Guidance-42663183/